The Chennai based Burgeon Pharmaceuticals Pvt. Ltd. launched a state-of-the-art manufacturing facility at Maraimalai Nagar, Kancheepuram district near Chennai, envisaging augmentation of the manufacturing activities by the company.
The new plant, with a built up area of 40,000 sq. ft. in four-acre premises, will focus on pain management, GI, psychotropic, cardiology, diabetology and anti-infective segments. The facility, with an investment of Rs 12 crore, has production capacity of 1326 tonne tablets, 375 tonne capsules and 24,96,000 litres of liquid per year.
The new R&D facility is intended to develop formulations and methods and plans are to expand the facilities compatible for API and Biotech NDAs in future, according to the company sources. The facility is built up to meet the specifications of MHRA, WHO Geneva, TGA and Schedule-M and the quality control facility is ready to comply with NABL accreditation eyeing on contract manufacturing and export prospects, they added.
Burgeon Pharma, established in 1995 with a range of pain management, diabetes and anti-infective products, was located at Pondicherry under loan licensee and had its marketing activities based at Chennai. By setting up its own plant, the company has also plans to foray into export market, initially by entering into the unregulated markets. The company plans to commence its export operations in Nigeria and Sri Lanka within the financial year. The company also revealed that its expansion plans includes exports to Maldives, Mauritius, Kenya, Niger, Togo, Chad, Ghana and Cameroon in future.
"We are also looking forward keenly for joint ventures with foreign companies for formulations and bulk drugs, setting up marketing activity and manufacturing at a later stage," K Manimaaran, Managing Director, Burgeon told Pharmabiz.
The Rs 20 crore Burgeon Pharmaceuticals has two divisions, Crates Inventions and Dew Formulations, to market some of the ethical products. The company has set up its goals for joint venture with foreign companies for formulations and bulk drugs, to foray into co-marketing opportunities with Biotech and Pharma fields both in India and abroad under JV / Brand acquisition and to set up 100per cent EOU in Bio-Tech Pharma sector in JV with equity partnership, added Manimaaran.